Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
MBRX similar filings
- 10 Apr 24 Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
- 8 Apr 24 Other Events
- 27 Mar 24 Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
- 25 Mar 24 Regulation FD Disclosure
- 25 Mar 24 Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
- 22 Mar 24 Moleculin Reports Full Year 2023 Financial Results
- 20 Mar 24 Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
Filing view
External links
Exhibit 99.1